Related Experiment Video
Updated: Jun 26, 2026

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
Published on: December 30, 2016
Precision metabolic therapy for propionic acidemia
Boopathi Subramaniyan1, Fang Lu2, Huan Li1
1Surgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ 08103, USA.
Insights
Propionic acidemia (PA) is a metabolic disorder where toxic buildup impairs cellular function. Combination therapies targeting short-chain fatty acid metabolism and CoA homeostasis offer a promising new strategy for treating PA.
Area of Science:
- Biochemistry
- Metabolic Disorders
- Genetics
Background:
- Propionic acidemia (PA) is a rare genetic disorder caused by propionyl-CoA carboxylase deficiency.
- Accumulation of propionyl-CoA and toxic metabolites disrupts cellular metabolism, leading to mitochondrial dysfunction and multi-organ pathology.
- Current treatments like dietary restriction and supportive therapies have suboptimal long-term outcomes.
Purpose of the Study:
- To review current understanding of PA pathophysiology and treatment limitations.
- To explore emerging therapeutic strategies, including gene-based and small-molecule approaches.
- To propose a novel combination therapy targeting short-chain fatty acid metabolism and CoA homeostasis.
Main Methods:
- Literature review of PA pathophysiology, current management, and novel therapeutic strategies.
- Analysis of metabolic pathways affected by propionyl-CoA accumulation.
- Conceptualization of a precision metabolic therapy combining multiple interventions.
Main Results:
- Propionyl-CoA accumulation disrupts TCA cycle flux, ammonia detoxification, and promotes oxidative stress.
- Existing treatments face challenges with tolerability, efficacy, and extrahepatic disease.
- Gene therapy and small molecules show promise but require further development.
- Emerging strategies focus on metabolic reprogramming and restoring CoA pools.
Conclusions:
- Rational combination therapy targeting multiple metabolic nodes is proposed as a superior strategy for PA.
- This approach aims to restore metabolic balance by addressing propionyl-CoA burden and CoA homeostasis.
- Precision metabolic therapy holds potential for improved long-term outcomes in PA patients.
Abstract:
Propionic acidemia (PA) is a rare autosomal recessive metabolic disorder caused by a deficiency of mitochondrial propionyl-CoA carboxylase, leading to the accumulation of propionyl-CoA and toxic metabolites that disrupt TCA cycle flux and ammonia detoxification. Propionyl-CoA is generated from gut microbiome-derived propionate, propiogenic amino acids, odd-chain fatty acids, and cholesterol side chains. Its accumulation produces downstream metabolites such as propionylcarnitine and methylcitrate and promotes histone propionylation. These alterations collectively contribute to mitochondrial dysfunction, oxidative stress, and multi-organ pathology. Current clinical management focuses on reducing propionyl-CoA burden through dietary restriction and supportive therapies, but long-term outcomes remain suboptimal due to poor tolerability and progressive complications. Although liver transplantation improves hepatic metabolism, it does not fully correct extrahepatic disease. Gene-based approaches, including mRNA-based enzyme replacement and viral vector-mediated gene delivery, show promise but face challenges related to delivery efficiency, durability of expression, and immune responses. Emerging small-molecule strategies aim to reprogram metabolism by restoring the balance between propionyl-CoA and acetyl-CoA while replenishing cellular CoA pools. Precision metabolic therapy may combine acetate supplementation and NRF2 activation to enhance acetyl-CoA production and mitochondrial resilience, while suppressing propionyl-CoA formation through ACSS3 inhibition and propiogenic amino acid restriction. In parallel, CoA availability may be increased through activation of PANK1-3, inhibition of PANK4, and supplementation with CoA precursor compounds. We propose that rational combination therapy targeting multiple nodes of short-chain fatty-acid metabolism and CoA homeostasis will provide a more effective strategy than single-agent approaches for correcting metabolic imbalance in PA.
Related Concept Videos
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Pyruvate Oxidation
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...

